Skip to main content
JAGX
NASDAQ Life Sciences

Jaguar Health Swaps $3.4M of Debt for 481,584 Shares with Streeterville

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$7.08
Mkt Cap
$4.005M
52W Low
$2.35
52W High
$1,280.948
52W Position info
201% above low
Off High info
99% below high
Rel. Volume info
26× avg
Market data snapshot near publication time

JAGX has more than doubled off its 52-week low of $2.35 on elevated volume (26× avg).

Summary

Jaguar Health exchanged $3.4 million of its 2021 Note for 481,584 newly issued shares, cutting secured debt but adding immediate resale overhang to a thinly traded stock.


Key Events · Financing and Capital Events · JAGX

  • Debt-for-Equity Exchange with Streeterville

    Issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 reduction in the outstanding balance of the 2021 Note.

  • Immediate Resale Overhang

    Exchange shares were issued under Section 3(a)(9) with no restrictive legend, allowing Streeterville to sell them immediately into the market.

  • Post-Exchange Share Count

    Company reports approximately 1,945,542 shares outstanding after the exchange, up from roughly 1.46 million shares prior to the issuance.

  • Balance Sheet Relief

    The $3.4 million debt reduction is significant relative to the company's $3.8 million cash balance and going concern warning disclosed in the Q2 2026 10-Q.


Analysis · JAGX · Life Sciences

A $3.4 million reduction in the outstanding 2021 Note balance was achieved by issuing 481,584 shares to Streeterville Capital. This eliminates a meaningful portion of secured debt for a company with only $3.8 million in cash and a going concern warning, but it also adds roughly 25% to the post-split share count of 1.95 million shares. Because the shares were issued without restrictive legends under Section 3(a)(9), Streeterville can sell them immediately, creating near-term selling pressure on a stock already trading at $7.08 after a 1-for-15 reverse split.

How filings like this one have moved

In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, JAGX was trading at $7.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $2.35 to $1,280.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

JAGX - Latest Insights

JAGX
Oct 29, 2026, 8:00 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $0.990201 info
Change: -$1.07 (-52%) info
Market Cap: $3.764M info
JAGX
Oct 22, 2026, 5:08 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $2.14
Real-time Price: $0.990201 info
Change: -$1.15 (-54%) info
Market Cap: $3.764M info
JAGX
Oct 14, 2026, 9:00 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $0.990201 info
Change: -$3.05 (-75%) info
Market Cap: $3.764M info
JAGX
Oct 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $4.50
Real-time Price: $0.990201 info
Change: -$3.51 (-78%) info
Market Cap: $3.764M info
JAGX
Oct 05, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $0.990201 info
Change: -$3.19 (-76%) info
Market Cap: $3.764M info